A practical 2026 guide to the Section 1031 like-kind exchange: how to defer capital gains and depreciation recapture on investment real estate, the 45-day and 180-day deadlines, qualified intermediaries, boot, identification rules, DSTs, and the mistakes that blow up an exchange.
A practical 2026 guide to using a donor-advised fund (DAF) as a tax strategy: how DAFs work, deduction bunching, gifting appreciated stock to skip capital gains, DAF vs private foundation, fees and providers, and the mistakes that quietly erase the benefit.
What US physician medical malpractice insurance actually costs, and why premiums swing from a few thousand dollars to well over six figures depending on specialty, state tort environment, claims-made versus occurrence coverage, tail exposure, and whether you are employed or in private practice.
What professional liability (errors and omissions, E&O) insurance costs in 2026, with annual premium ranges by profession, the factors that move your rate, claims-made vs occurrence and tail coverage explained, plus how to compare quotes and the mistakes that leave US professionals underinsured.
A practical U.S. guide to birth-injury and cerebral palsy medical-malpractice claims: which standard-of-care failures get litigated, how hypoxia and delayed C-sections are argued, statute-of-limitations basics with minors' tolling, the medical records that matter, how contingency fees and expert witnesses work, how to choose a birth-injury attorney, and the mistakes that sink cases.
A plain-English 2026 guide to the Tylenol (acetaminophen) prenatal-use autism and ADHD litigation: the MDL 3043 history and the expert-testimony ruling, the association-versus-causation science, who may qualify, how mass torts and contingency fees actually work, deadlines, and common mistakes.
A balanced C3.ai (ticker AI) 2026 stock analysis: the enterprise AI application platform, partner-led go-to-market with hyperscalers and defense, the consumption-pricing transition, persistent GAAP losses and stock-based comp dilution, and how it stacks up against Palantir and Snowflake.
A deep, qualitative 2026 outlook on Essential Utilities (NYSE: WTRG): rate-base growth through Aqua water M&A and Peoples natural gas, the fragmented municipal roll-up, dividend-aristocrat compounding, regulatory lag, interest-rate sensitivity, and capex funding.
BHP Group (BHP) 2026 stock outlook. A deep qualitative look at the Pilbara iron ore (WAIO) cash engine, the copper growth pivot (Escondida, Copper South Australia, potential M&A) as an energy-transition metal, Jansen potash optionality, China steel and property demand, commodity cyclicality, and the ADR dividend structure for US investors.
Charter Communications (CHTR) 2026 stock outlook. A qualitative deep dive into Spectrum broadband subscriber pressure from fixed-wireless and fiber overbuild, Spectrum Mobile's MVNO growth engine, the pending Cox combination as a 2026 catalyst, and the heavy free-cash-flow buyback model built on high leverage.
Caesars Entertainment (CZR) 2026 stock outlook. A deep, qualitative look at how Las Vegas and regional casino EBITDA funds debt paydown, the Caesars Digital (online sports betting and iGaming) path to profit, the Caesars Rewards loyalty engine, and why high leverage is the swing factor that amplifies both upside and downside for US investors.
Advance Auto Parts (AAP) 2026 stock outlook. Store and distribution-center rationalization, DIFM (pro) versus DIY mix, margin recovery, share loss to AutoZone, O'Reilly, and Genuine Parts, plus the dividend cut and Worldpac sale, in a balanced deep dive on this auto-aftermarket turnaround.
QGEN (Qiagen) stock outlook for 2026. A deep qualitative look at the razor-and-blade sample-prep model, the QuantiFERON-TB franchise, QIAstat-Dx syndromic testing and digital PCR, how it stacks up against Roche, Danaher and Cepheid, bioMerieux and Hologic, plus slower growth and FX risk for US investors.
TE Connectivity (TEL) stock outlook for 2026. A qualitative deep dive into the connector and sensor franchise, AI-datacenter high-speed content growth, rising connector content per electric vehicle, the Transportation and Industrial segments, the Amphenol rivalry, and auto-production cyclicality risk.
CGNX (Cognex) 2026 stock outlook. A grounded look at machine-vision leadership, exposure to logistics, EV-battery and semiconductor capex cycles, the Keyence rivalry, project versus recurring revenue, and the debt-free balance sheet that gets Cognex through the down years.
Aptiv (APTV) stock outlook for 2026: a deep qualitative read on its electrical-architecture and ADAS software franchise, the planned Electrical Distribution Systems (EDS) spin-off as the key 2026 catalyst, auto-production cyclicality and EV-adoption risk, plus how it stacks up against BorgWarner, Sensata and TE Connectivity.
DL (000210) DL Holdings (formerly Daelim Industrial) 2026 stock outlook. A qualitative deep dive into the net-asset-value holding-company discount, the DL E&C and DL Chemical subsidiary earnings link, dividend, trademark-royalty and rental income, and shareholder returns for foreign investors.
Infac (KRX: 023810) 2026 stock outlook. A deep look at the control-cable core business supplying Hyundai and Kia, the mechatronics shift into electronic parking brakes (EPB), hydrogen and electrification parts, and the automaker dependence and currency sensitivity that drive this Korean small-cap.
Macquarie Korea Infrastructure Fund (MKIF, KOSPI 088980) 2026 outlook: how toll roads, tunnels and ports generate distributions, why the price is rate-sensitive, concession-expiry and asset-recycling risk, and how foreign investors handle Korean dividend withholding and FX.
SK REIT (395400) 2026 outlook analyzing its quarterly-dividend structure, the SK Seorin office tower, gas-station sale-and-leaseback and data-center assets, the SK sponsor acquisition pipeline, interest-rate sensitivity, and refinancing and equity-dilution risk for US investors.
Sunjin (KOSPI 136490) 2026 stock outlook for US-based investors. How feed, hog farming, and meat processing chain together, why the corn-to-pork spread drives earnings, the Sunjin Pork processing arm, whether a low-PBR livestock re-rating can happen, plus ASF and feed-grain risk explained in plain English.
HLB Life Science (067630) 2026 stock outlook. An honest, qualitative breakdown of the HLB Group rivoceranib anticancer FDA re-filing narrative, what it means to be a value-chain proxy rather than the lead applicant, the group cross-shareholding and dilution risk, and why this is a binary event-driven biotech, not a fundamentals story.
Mirae Semiconductor (254490) 2026 stock outlook. A qualitative deep dive into its role as an official Samsung memory and system-chip distributor, the world's only Samsung memory AS center, the AI-memory demand leverage, and the thin-margin distribution reality of receivables and inventory risk.
Nextchip (KOSDAQ 396270) 2026 stock outlook. A qualitative deep dive into the automotive ADAS image-processor fabless: the Apache ISP and SoC roadmap, why rising camera counts drive the story, the fabless model's trade-offs, competition with Ambarella and Mobileye, and what US investors should watch on tax and FX.